CD80 Protein (CD80) (AA 37-245, N-Term)

Catalog No. ABIN2666531

Product Details

Target: CD80

Protein Type: Recombinant

Biological Activity: Active

Protein Characteristics: AA 37-245, N-Term

Origin: Mouse

Source: CHO Cells

Application: Flow Cytometry (FACS)

Purity: > 95 % , as determined by Coomassie stained SDS-PAGE.

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 1.0 EU per μg of protein as determine by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: Immobilized mouse B7.1 induces proliferation of human T cells in the presence of anti-human CD3. The ED50 is 2.25 - 9.0 μg/mL. In addition, mouse B7.1 induces IL-2 production on activated T cells. Results may vary depending on human donors.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. Stock solutions can also be prepared at 50 - 100 μg/mL in sterile buffer (PBS, HPBS, DPBS, or EBSS) containing carrier protein such as 0.2 - 1 % BSA or HSA and stored in working aliquots at -20 °C to -70 °C.

Concentration: 200 μg/mL

Buffer: 0.22 μm filtered protein solution is in PBS.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for one month, at -20°C for six months, or at -70°C for one year.

Target Details

Target: CD80

Alternative Name: B7.1 (CD80 Products)

Synonyms: B7 Protein, B7-1 Protein, B7.1 Protein, BB1 Protein, CD28LG Protein, CD28LG1 Protein, LAB7 Protein, B71 Protein, Cd28l Protein, Ly-53 Protein, Ly53 Protein, MIC17 Protein, TSA1 Protein, CD80 molecule Protein, Cd80 molecule Protein, CD80 antigen Protein, CD80 Protein, Cd80 Protein

Background: The B7 family of proteins are structurally related, cell membrane-associated molecules that regulate immune responses by delivering costimulatory or coinhibitory signals via their ligands. So far, eight family members have been identified, including B7.1, B7.2, B7-H1, B7-H2, B7-H4, B7-H6, PD-L1, and PD-L2. These proteins are mainly expressed by activated antigen presenting cells (APCs) and when paired with either CD28 or CTLA-4 on a T lymphocyte, they induce an increase or decrease in the downstream signaling activity of the MHC-TCR interaction between APCs and T cells. B7.1 has been shown to bind both CTLA-4 and CD28, however, it has a 20-fold higher affinity to CTLA-4 than to CD28. Despite their structural similarities, the individual contribution of B7.1 and B7.2 to the development of pathogenic T cells in autoimmune diseases and protective T cells in infectious diseases is markedly distinct. Besides regulating T cell immune responses, B7 also plays a role in anti-tumor immunity. This is confirmed by demostrating that cytotoxic T cells were able to eradicate tumor cells transfected with B7.1 and B7.2. After activation, follicular lymphoma was shown to upregulate B7.1 and other costimulatory and adhesion molecules, therefore increasing APC activity and amplifying primed T cell responses. Homozygous null B7.1/B7.2 mice fail to generate antigen specific IgG1 and IgG2a responses, suggesting that B7 proteins are important in Ig immune responses. Mouse and human B7.1 share 44 % amino acid identity.

Molecular Weight: The 449 amino acid recombinant protein has a predicted molecular mass of approximately 51 kDa. The protein migrates at approximately 72 kDa in DTT-reducing conditions and at approximately 150 kDa in non-reducing conditions by SDS-PAGE. The predicted N-ter

Pathways: TCR Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints